Relmada Therapeutics (RLMD) Enterprise Value (2012 - 2026)
Relmada Therapeutics (RLMD) reported Enterprise Value of -$234.0 million for Q1 2026, down 764.58% year-over-year from $35.2 million in Q1 2025, and down 151.56% quarter-over-quarter from -$93.0 million in Q4 2025.
Relmada Therapeutics (RLMD) Enterprise Value (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Enterprise Value data on file, last reported at -$234.0 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$234.0 million, down 764.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$234.0 million (down 764.58% YoY), and the FY2025 annual result was -$93.0 million, down 107.1% from the prior year.
- Enterprise Value fell to -$234.0 million in Q1 2026 per RLMD's latest filing, from -$93.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$13.9 million in Q3 2025 and troughed at -$234.0 million in Q1 2026.
- A 5-year average of -$109.4 million and a median of -$96.3 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value surged 74.34% in 2025, then tumbled 764.58% in 2026.
- A 5-year view of Enterprise Value shows it stood at -$148.3 million in 2022, then surged by 35.06% to -$96.3 million in 2023, then jumped by 53.38% to -$44.9 million in 2024, then tumbled by 107.1% to -$93.0 million in 2025, then slumped by 151.56% to -$234.0 million in 2026.
- Business Quant data shows RLMD's Enterprise Value at -$234.0 million in Q1 2026, -$93.0 million in Q4 2025, and -$13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -233.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -233.96 Mn |
| Dec 31, 2025 | -93.01 Mn |
| Sep 30, 2025 | -13.89 Mn |
| Jun 30, 2025 | -20.62 Mn |
| Mar 31, 2025 | -27.06 Mn |
| Dec 31, 2024 | -44.91 Mn |
| Sep 30, 2024 | -54.12 Mn |
| Jun 30, 2024 | -70.44 Mn |
| Mar 31, 2024 | -83.61 Mn |
| Dec 31, 2023 | -96.32 Mn |
| Sep 30, 2023 | -106.27 Mn |
| Jun 30, 2023 | -118.53 Mn |
| Mar 31, 2023 | -132.44 Mn |
| Dec 31, 2022 | -148.32 Mn |
| Sep 30, 2022 | -184.15 Mn |
| Jun 30, 2022 | -211.96 Mn |
| Mar 31, 2022 | -220.65 Mn |
| Dec 31, 2021 | -211.91 Mn |
| Sep 30, 2021 | -88.09 Mn |
| Jun 30, 2021 | -109.07 Mn |